Phase II Study of Fulvestrant (Faslodex) in Androgen Independent Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2013
At a glance
- Drugs Fulvestrant (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 24 Jan 2013 Planned end date changed from 1 Jun 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.